[1] [1] PETRELLA F, RIZZO S, ATTILI I, et al. StageⅢnon-smallcell lung cancer: an overview of treatment options[J]. Curr Oncol, 2023, 30(3): 3160-3175.

[2] [2] PARVEZ A, CHOUDHARY F, MUDGAL P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment[J]. Front Immunol, 2023, 14: 1296341.

[3] [3] KAUFMAN B, ABRAMOV O, IEVKO A, et al. Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer[J]. Sci Adv, 2023, 9(21): eadg2809.

[4] [4] NGUYEN V Q, GEIRNAERT M. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)[J]. J Oncol Pharm Pract, 2023, 29 (2): 450-456.

[5] [5] CHHOURI H, ALEXANDRE D, GRUMOLATO L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer[J]. Cancers, 2023, 15(2): 504.

[6] [6] ABAZA A, IDRIS F S, SHAIKH H A, et al. Programmed cell death protein 1(PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics[J]. Cureus, 2023, 15(9): e44582.

[7] [7] BOYK A, NICOM. The overview of perspectives of clinical application of liquid biopsy in non-small-cell lung cancer[J]. Life, 2022, 12(10): 1640.

[8] [8] CABALL-PEREZ E, HERNNDEZ-PEDRON, RAMOSRAMREZ M, et al. Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes[J]. Clin Transl Oncol, 2024, 26(4): 836-850.

[9] [9] SHEN M, QI R, REN J, et al. Characterization with KRAS mutant is a critical determinant in immunotherapy and other multiple therapies for non-small cell lung cancer[J]. Front Oncol, 2022, 11: 780655.

[10] [10] DAVIS A P, COOPER W A, BOYER M, et al. Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations[J]. Immunotherapy-UK, 2021, 13(11): 941-952.

[11] [11] THOMAS Q, LEMERCIER P, JUSTEAU G, et al.1401P impact of KRAS mutation on non-small cell lung cancer survival outcomes[J]. Ann Oncol, 2023, 34: S802.

[12] [12] GAO S, LI N, GAO S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.

[13] [13] GUO J, SHU T, ZHANG H, et al. A combined model of serum neutrophil extracellular traps, CD8+T cells, and tumor proportion score provides better prediction of PD 1 inhibitor efficacy in patients with NSCLC[J]. FEBS J, 2024, 291(15): 3403-3416.

[14] [14] CHEN L, XIE J, ZHU M, et al. The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations[J]. Transl Cancer Res, 2024, 13(1): 137.

[15] [15] TANCO V, BLICHROV A, PLANK L. Programmed death-ligand 1 expression in non-small cell lung carcinoma-mechanism of regulation, association with other markers, and therapeutic implication[J]. Klin Onkol, 2022, 35(5): 372-376.

[16] [16] XIONG A, XU J, WANG S, et al. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer[J]. Front Immunol, 2023, 14: 1173025.

[17] [17] HIMURO H, NAKAHARA Y, IGARASHI Y, et al. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors[J]. Cancer Immunol Immu, 2023, 72(8): 2829-2840.

[18] [18] SO W Q V, DEJARDIN D, ROSSMANN E, et al. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data[J]. J Immunother Cancer, 2023, 11(2), 11(2): e006464.

[19] [19] MANI S, LAKSHMANAN A, SUBRAMANYAN A. Assessment of programmed cell death ligand-1 expression in non-small cell lung carcinomas by immunohistochemistry[J]. Apollo Med, 2024, 21(1): 57-61.

[20] [20] ZHU X, SUN L, SONG N, et al. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stageⅡ-ⅢNSCLC (LungMate 002): an open-label, single-arm, phase 2 trial[J]. BMC Med, 2022, 20(1): 493.

[21] [21] OLINGY C, ALIMADADI A, ARAUJO D J, et al. CD33 expression on peripheral blood monocytes predicts efficacy of anti-PD-1 immunotherapy against non-small cell lung cancer[J]. Front Immunol, 2022, 13: 842653.

[22] [22] MEI J, JIANG G, CHEN Y, et al. HLA classⅡmolecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC[J]. BMC Cancer, 2022, 22(1): 738.

[23] [23] FANG Q, YU J, LI W, et al. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy[J]. Clin Exp Pharmacol P, 2023, 50(2): 178-190.

[24] [24] QIANG H, ZHONG H.467 A real-world retrospective study of immunotherapy in NSCLC patients with KRAS mutation[J]. J Immunother Cancer, 2023, 11(Sup1): 1.

[25] [25] CHMIELEWSKA I, KRAWCZYK P, GRENDA A, et al. Breaking the ‘undruggable’ barrier: anti-PD-1/PD-L1 immunotherapy for non-small cell lung cancer patients with KRAS mutations—a comprehensive review and description of single site experience[J]. Cancers, 2023, 15(14): 3732.

[26] [26] PINTO L M, ROCHA P, CLAVE S, et al.193P differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC[J]. J Thorac Oncol, 2023, 18 (4): S145-S146.

[27] [27] NOORDHOF A L, SWART E M, DAMHUIS R A M, et al. Prognostic implication of KRAS G12C mutation in a real-world KRAS-mutated stage IV NSCLC cohort treated with immunotherapy in The Netherlands[J]. JTO Clin Res Rep, 2023, 4 (9): 100543.

[28] [28] PRINCIPE D R, PASQUINELLI M M, NGUYEN R H, et al. Loss of STK11 suppresses lipid metabolism and attenuates KRAS-induced immunogenicity in patients with non-small cell lung cancer[J]. Cancer Res Commun, 2024, 4(8): 2282-2294.